On the Enhanced Antibacterial Activity of Antibiotics Mixed with Gold Nanoparticles
© to the authors 2009
Received: 17 December 2008
Accepted: 6 April 2009
Published: 21 April 2009
The bacterial action of gentamicin and that of a mixture of gentamicin and 15-nm colloidal-gold particles onEscherichia coli K12 was examined by the agar-well-diffusion method, enumeration of colony-forming units, and turbidimetry. Addition of gentamicin to colloidal gold changed the gold color and extinction spectrum. Within the experimental errors, there were no significant differences in antibacterial activity between pure gentamicin and its mixture with gold nanoparticles (NPs). Atomic absorption spectroscopy showed that upon application of the gentamicin-particle mixture, there were no gold NPs in the zone of bacterial-growth suppression in agar. Yet, free NPs diffused into the agar. These facts are in conflict with the earlier findings indicating an enhancement of the bacterial activity of similar gentamicin–gold nanoparticle mixtures. The possible causes for these discrepancies are discussed, and the suggestion is made that a necessary condition for enhancement of antibacterial activity is the preparation of stable conjugates of NPs coated with the antibiotic molecules.
KeywordsColloidal-gold nanoparticles Gentamicin Drug delivery Antibacterial activity Agar-well-diffusion method Minimum inhibitory concentration Maximum tolerant concentration Atomic absorption spectroscopy
Over the recent decade, gold nanoparticles (NPs) [1–3] have attracted significant interest as a novel platform for various applications such as nanobiotechnology and biomedicine [4–7] because of convenient surface bioconjugation  with molecular probes and remarkable plasmon-resonant optical properties . Recently published examples include applications of NPs to biosensorics , genomics [11, 12], clinical chemistry , immunoassays , immune response enhancement , detection and control of microorganisms , optical imaging of biological cells (including cancer cell imaging with resonance scattering [17, 18], optical coherence tomography , two-photon luminescence , and photoacoustic [21, 22] techniques), cancer cell photothermolysis [23, 24], and targeted delivery of drugs or genetic and immunological substances [25–29]. In particular, there is great interest in the development of nanoparticle-based vectors that decrease the toxicity of free drugs and ensure targeted delivery directly to tumor cells [30–33]. Gold NPs have been used for delivery of not only antitumor agents, but also insulin , tocopherol , and other drugs [16, 29].
Conjugates of gold NPs with antibiotics and antibodies also have been used for selective photothermal killing of protozoa and bacteria [36–38]. In regard to antibacterial activity, Williams et al.  showed that gold NPs themselves do not affect bacterial growth or functional activity, whereas conjugates of vancomycin to gold NPs decrease the number of growing bacterial cells . Gu et al.  synthesized stable gold NPs covered with vancomycin and showed significant enhancement of antibacterial activity for this conjugate, in comparison with the activity of the free antibiotic. A similar result was reported for ciprofloxacin conjugated with Au/SiO2 core/shell NPs .
In contrast to gold NPs, silver NPs may exhibit antibacterial activity . Furthermore, silver NPs were shown to enhance the antibacterial activity of penicillin G, amoxicillin, erythromycin, clindamycin, and vancomycin against Staphylococcus aureus and Escherichia coli. Similar conclusions were reported on the antibacterial activity of silver and gold NPs stabilized with hyperbranched poly(amidoamine), containing terminal dimethylamine groups .
It should be emphasized that in the above-cited studies [37, 40, 41], the authors used NPs functionalized with antibiotics by physical or chemical adsorption. Compared with bare NPs, stable conjugates exhibited small changes in the absorption spectra. For the naked eye, the conjugated sols retained their red color, typical of colloidal-gold sols.
In 2007, four papers have been published [45–48], reporting the use of blue aggregated mixtures of drugs and GNPs, rather than of stable red conjugates. Such a color change and transmission electron microscopy (TEM) images unambiguously indicated NP aggregation . The drugs used were aminoglycoside antibiotics (streptomycin, gentamicin, kanamycin, and neomycin), quinolones (ciprofloxacin, gatifloxacin, and norfloxacin), ampicillin (a penicillin antibiotic), and 5-fluorouracil (an antimetabolite of nucleic metabolism). The preparations obtained by the authors were tested for antibacterial activity toward gram-positive (S. aureus Micrococcus luteus) and gram-negative (E. coli Pseudomonas aeruginosa) microorganisms, and they also were examined for antifungal activity toward Aspergillus fumigatus and Aspergillus niger. The basic experimental tests for the determination of antibacterial activity were the disk diffusion method [45, 46, 48] and the agar-well-diffusion method . Depending on the antibiotic used, increase in the activity of the antibiotic–colloidal-gold mixture ranged from 12 to 40%, as compared with the activities of the native drugs. From those data, the authors concluded that the antibacterial activities of the antibiotics were enhanced through the use of gold NPs [45–48].
However, as noted by the authors themselves [43–48], the question of the mechanisms governing possible enhancement of the antibacterial action of drugs or polymers remains unanswered. Whereas several hypotheses have been raised for aggregatively stable NP–antibiotic conjugates , the enhancement mechanism for aggregated NP–antibiotic mixtures—if it exists at all—is absolutely incomprehensible, at least when the activity of preparations is assessed by the agar-well-diffusion method. First, no gold NPs have been shown to be present in the agar zone of bacterial-growth inhibition. Antibiotic addition to an NP suspension leads to NP aggregation, readily detectable with extinction spectra and with TEM images. The question now arises, can particle aggregates diffuse into agar at all? Let us suggest for a moment that diffusion is impossible. In that case, the question of enhancement of antibacterial action loses its meaning altogether. Here, therefore, we decided to examine the antibacterial activity of an NP–antibiotic mixture and to simultaneously investigate the penetration of particles into agar.
We explored the antibacterial activity of a mixture of gentamicin and colloidal-gold particles (average diameter, 15 nm) toward E. coli К12, by using the agar-well-diffusion method, enumeration of colony-forming units (CFUs), and turbidimetry. Gentamicin was chosen on the basis of the following reasons. First, as an aminoglycoside antibiotic, gentamicin is of unquestionable practical interest. Being a mixture of gentamicins C1, C2, and C1a, it is bacteriostatic to many gram-positive and gram-negative microorganisms, including E. coli Proteus Salmonella, and penicillin-resistant Staphylococcus strains. The mechanism of gentamicin action is linked to disruption of ribosomal synthesis of protein, and microbial resistance to gentamicin develops fairly slowly. Gentamicin is a major agent used to treat severe purulent infection, especially that caused by a resistant gram-negative flora. As a broad-spectrum antibiotic, gentamicin is often prescribed for patients with mixed infection and also when the infecting agent has not been identified. Sometimes gentamicin is effective when other antibiotics display insufficient activity .
Second, gentamicin was chosen because, as found previously , a mixture of gentamicin and gold NPs has the most enhanced activity toward E. coli. It is this result, along with the need to study particle penetration into agar, that prompted this research.
Preparation of Gold NPs
Gold NPs were prepared by the reduction of tetrachloroauric acid with sodium citrate . A 242.5-mL portion of 0.01% aqueous tetrachloroauric acid (Aldrich, USA) was heated on an MR 3001 magnetic stirrer (Heidolph, Germany) in an Erlenmeyer flask fitted with a water-cooled reflux tube. This was followed by the addition of 7.5 mL of 1% aqueous sodium citrate (Fluka, Switzerland) to the flask. The mean particle diameter (16 nm) was controlled by spectrophotometric calibration .
Preparation of a Gentamicin–NP Mixture
We used an aqueous stock solution of gentamicin sulfate (Fluka, Switzerland; activity, 636 U mg−1; concentration, 4.5 mg mg−1). Immediately before being added to the culture medium or to the gel wells, the antibiotic solution was mixed 1:1 either with 2 mM K2CO3or with gold NPs in the same solution. In agar-well-diffusion experiments, we also made a series of twofold dilutions of the free-gentamicin solution and of the gentamicin–NP mixture.
Antibacterial action of gentamicin and a gentamicin–NP mixture onE. coli K12
Gentamicin concentration (mg mL−1)
Inhibition-zone diameter (mm)
Gentamicin + NPs
9.9 ± 0.6
9.9 ± 0.6
11.6 ± 0.2
11.5 ± 0.2
12.3 ± 0.6
12.1 ± 0.55
Bacterial Strain and Growth Conditions
E. coli К12 obtained from this institute’s collection was used for this study. The strain was grown in Luria–Bertani (LB) medium at 37 °C. All inoculation experiments used an overnight accumulation culture grown to stationary phase in advance. The initial culture absorbance A600 was 0.04. Bacterial growth was assessed by using the time-dependent absorbance curve. The cell concentration was estimated by the turbidity-spectra method .
A bacterial suspension was mixed 1:1 with either a free-gentamicin solution or a gentamicin–NP mixture and was incubated at 37 °C for 1 h. For each treatment, six 10-fold serial dilutions were made. A 200-μL volume of the resultant suspension was uniformly spread onto overnight-dried solid LB medium with a sterile spatula. After cultivation at 37 °C for 24 h, all the colonies grown were enumerated, and the mean values and maximal scatter in CFUs were determined.
Antibacterial activity was studied by the agar-well-diffusion method, wherein a bacterial suspension was added to sterile nutrient agar at 45 °C and the mixture was solidified on a Petri dish. A 20-mL volume of the medium was poured into a Petri dish (diameter, 90 mm) on a horizontally leveled surface. After the medium had solidified, 4-mm-diameter wells were made in the agar (at six wells per dish) that were equidistant from one another and from the dish edge. The wells received either 20 μL of the free-antibiotic solution or 20 μL of the antibiotic–NP mixture. The Petri dishes were incubated in a thermostat at 37 °C for 24 h. After incubation, the diameter of the zone of bacterial-growth inhibition was measured with an accuracy of ±0.1 mm. The mean inhibition-zone diameter and the maximal data scatter also were determined. All experiments were repeated thrice.
Determination of the Minimum Inhibitory and Maximum Tolerant Concentrations
In experiments to determine the minimum inhibitory concentration (MIC) and the maximum tolerant concentration (MTC, equivalent to the “no observed effect concentration”), culturing was done in microtitration-plate wells for 3 h. The initial culture absorbance A600was 0.04. The MIC was taken to be the gentamicin concentration at which the A600of the bacterial suspension after incubation was almost the same as the initial A600, and the MTC was numerically equal to the gentamicin concentration at which the parameters of culture growth were close to those for the control culture (without the antibiotic).
Atomic Absorption Spectroscopy
Ashing of samples was done with the addition of sulfuric acid at 600–630 °C. The ash was then dissolved in a mixture of concentrated hydrochloric and nitric acids. The solution was evaporated to dryness, a necessary amount of 0.5 N hydrochloric acid was added, and the sample thus prepared was analyzed for gold on an AAS-3 atomic absorption spectrometer (Carl Zeiss, Germany). The resonance line was 242.8 nm, and the spectral slit width was 0.35 nm. Under such conditions, the limit of detection is 0.02 μg mL−1and the linear working region is up to 20 μg mL−1.
Results and Discussion
Effect of the Antibiotic Concentration
Effect of the Residual Particles and Supernatant Liquids
We found (Fig. 3, wells 3 and 4) that the sediment NPs did not cause the formation of a zone of culture-growth inhibition at all. Yet, the supernatant liquids resulting from centrifugation had the same degree of activity toward bacterial growth as did the initial gentamicin–NP mixture (Fig. 3, wells 7 and 8). We emphasize once again that in our control experiments, neither colloidal gold itself nor solvent (2 mM K2CO3) inhibited bacterial growth (Fig. 3, wells 5 and 6).
Effect of the NP Concentration
Diffusion of Free Gentamicin and Its Complexes with NPs into Agar
Analysis of gold content in the gel samples cut out around the wells at 24 h after the application of an NP solution and a gentamicin–NP mixture
Fraction of the total Au mass in the sample (%)
Au in 1.5% agar gel
9.3 × 10−4
Gm + Au in 1.5% agar gel
Au in solid LB medium
3.2 × 10−4
Gm + Au in solid LB medium
Experiments with Bacterial Suspensions
The MICs and MTCs of gentamicin and a gentamicin–NP mixture added to growingE. coli K12 cells
MIC (μg mL−1)
MTC (μg mL−1)
Gm + Au
Comparison of the Bactericidal Effects of Gentamicin and a Gentamicin–NP Mixture
The results of CFU counts after culturing on solid LB medium
CFU (cells mL−1)
240 μg of the antibiotic per milliliter
3.7 μg of the antibiotic per milliliter
4.8 ± 0.4 × 109
4.6 ± 0.5 × 109
3.6 ± 0.9 × 109
2.8 ± 0.6 × 109
1.8 ± 0.5 × 109
Gm + NPs
0.96 ± 0.5 × 109
Table 4shows that gentamicin at 240 μg mL−1was bactericidal to 50 × 106bacterial cells mL−1both in a free state and in complex with NPs. The NPs decreased the CFU value, as compared with the control, but these differences were not significant. At a gentamicin concentration of 3.7 μg mL−1, the difference between the CFU values for free gentamicin and for the mixture was almost twofold, with the addition of NPs decreasing, not increasing, the bactericidal action of the antibiotic. However, because the CFU method is usually in error by an order of magnitude, this difference between the CFU values for gentamicin and for its mixture with NPs is not significant.
By using several methods, we have studied the effect of 16-nm gold NPs on the antibacterial activity of gentamicin. Within the limits of experimental error, no differences have been found between the antibacterial activity of gentamicin and that of a gentamicin–gold NP mixture at various gentamicin and particle concentrations. Sedimented gold NPs from the conjugates had no antibacterial activity, whereas the supernatant liquids from gentamicin–NP mixtures and free gentamicin demonstrated the same activity. Electron microscopy and the changes in the extinction spectra showed the presence of NP aggregates, which, on evidence derived by AAS, could not penetrate into gel. This explains the absence of growth inhibition upon addition of NP sediment to the wells. Furthermore, the same degree of activity of free gentamicin and the mixtures indicates that the amount of antibiotic that could bind to the particles is small. By the CFU method, we have found that the bactericidal action of a gentamicin–NP mixture does not differ from that of free gentamicin within the limits of error. Finally, the parameters of growth inhibition in a liquid bacterial culture (MIC and MTC) also were the same for gentamicin and for the gentamicin–NP mixture. In all our experiments, therefore, we have found no significant differences in antibacterial activity between the free antibiotic and the mixture either on a solid or in a liquid nutrient medium. Comparison of these data with the findings in the literature [37, 40, 41], showing enhancement of antibacterial activity in the presence of NPs, suggests that two conditions at minimum are necessary (but insufficient) for such effects to be observed. First, antibiotic–NP conjugates should be stabilized, and their spectrum and color should correspond to those of single-particle nonaggregated colloids. Second, the amount of the antibiotic covering the particle surface should be large enough to ensure an increase in the local antibiotic concentration at the site of bacterium–particle contact. Thus, although gold NPs themselves do not have any antimicrobial activity, they may act as drug curriers. In other words, because of the presence of gold NPs, the surface area increases and hence it carries a lot of drug on its surface. Obviously, when the amount of drug in proximity of a bacterium is more, the antibacterial property may be enhanced. For other possible explanations, the readers are referred to Ref. . In our opinion, the mechanism(s) of possible enhancement of the antibacterial activity of conjugates is still an open question and needs further study.
This study was partially supported by grants from the Russian Foundation for Basic Research (Nos. 07-04-00301a, 07-04-00302a, 07-02-01434-a, 08-02-00399, and 09-02-00496-a), CRDF BRHE Annex (Y4-B-06-01), the Ministry of Science and Education of the Russian Federation by a Program on the Development of High School Potential (No. 18.104.22.168/2950), and from the Presidium of RAS Program “The Basic Sciences—to Medicine.” We thank Mr. D.N. Tychinin (IBPPM RAS) for help in preparation of the manuscript.
- Daniel MC, Astruc D: Chem. Rev.. 2004, 104: 293. COI number [1:CAS:528:DC%2BD3sXpvFGlur0%3D] 10.1021/cr030698+View ArticleGoogle Scholar
- Dykman LA, Bogatyrev VA: Russ. Chem. Rev.. 2007, 76: 181. COI number [1:CAS:528:DC%2BD2sXlt1Oms74%3D] 10.1070/RC2007v076n02ABEH003673View ArticleGoogle Scholar
- Cheng MM, Cuda G, Bunimovich YL, Gaspari M, Heath JR, Hill HD, Mirkin CA, Nijdam AJ, Terracciano R, Thundat T, Ferrari M: Curr. Opin. Chem. Biol.. 2006, 10: 11. COI number [1:CAS:528:DC%2BD28XhtlGnt7g%3D] 10.1016/j.cbpa.2006.01.006View ArticleGoogle Scholar
- Liao H, Nehl CL, Hafner JH: Nanomedicine. 2006, 1: 201. COI number [1:CAS:528:DC%2BD28XpsFKisLw%3D] 10.2217/17435822.214.171.124View ArticleGoogle Scholar
- Hu M, Chen J, Li Z-Y, Au L, Hartland GV, Li X, Marqueze M, Xia Y: Chem. Soc. Rev.. 2006, 35: 1084. COI number [1:CAS:528:DC%2BD28XhtFSgtL%2FK] 10.1039/b517615hView ArticleGoogle Scholar
- Shim S-Y, Lim D-K, Nam J-M: Nanomedicine. 2008, 3: 215. COI number [1:CAS:528:DC%2BD1cXktFyjt7s%3D] 10.2217/174358126.96.36.199View ArticleGoogle Scholar
- Glomm WR: J. Dispersion Sci. Technol.. 2005, 26: 389. COI number [1:CAS:528:DC%2BD2MXktFKlt70%3D] 10.1081/DIS-200052457View ArticleGoogle Scholar
- Kreibig U, Vollmer M: Optical Properties of Metal Clusters. Springer-Verlag, Berlin; 1995.View ArticleGoogle Scholar
- Stewart ME, Anderton CR, Thompson LB, Maria J, Gray SK, Rogers JA, Nuzzo RG: Chem. Rev.. 2008, 108: 494. COI number [1:CAS:528:DC%2BD1cXhtFOnu74%3D] 10.1021/cr068126nView ArticleGoogle Scholar
- Rosi NL, Mirkin CA: Chem. Rev.. 2005, 105: 1547. COI number [1:CAS:528:DC%2BD2MXisVymsLk%3D] 10.1021/cr030067fView ArticleGoogle Scholar
- Liu X, Dai Q, Austin L, Coutts J, Knowles G, Zou J, Chen H, Huo Q: J. Am. Chem. Soc.. 2008, 130: 2780. COI number [1:CAS:528:DC%2BD1cXhsF2rtbc%3D] 10.1021/ja711298bView ArticleGoogle Scholar
- Baptista P, Pereira E, Eaton P, Doria G, Miranda A, Gomes I, Quaresma P, Franco R: Anal. Bioanal. Chem.. 2008, 391: 943. COI number [1:CAS:528:DC%2BD1cXlvFKnsr0%3D] 10.1007/s00216-007-1768-zView ArticleGoogle Scholar
- Gupta S, Huda S, Kilpatrick PK, Velev OD: Anal. Chem.. 2007, 79: 3810. COI number [1:CAS:528:DC%2BD2sXktVyhurc%3D] 10.1021/ac062341mView ArticleGoogle Scholar
- Dykman LA, Sumaroka MV, Staroverov SA, Zaitseva IS, Bogatyrev VA: Biol. Bull.. 2004, 31: 75. COI number [1:CAS:528:DC%2BD2cXovVGhug%3D%3D] 10.1023/B:BIBU.0000014358.98422.9cView ArticleGoogle Scholar
- Luo PG, Stutzenberger FJ: Adv. Appl. Microbiol.. 2008, 63: 145. COI number [1:CAS:528:DC%2BD1cXpsVKru7g%3D] 10.1016/S0065-2164(07)00004-4View ArticleGoogle Scholar
- El-Sayed IH, Huang X, El-Sayed MA: Nano Lett.. 2005, 5: 829. ; COI number [1:CAS:528:DC%2BD2MXjt1SmtLg%3D]; Bibcode number [2005NanoL...5..829E] 10.1021/nl050074eView ArticleGoogle Scholar
- Aaron J, de la Rosa E, Travis K, Harrison N, Burt J, José-Yakamán M, Sokolov K: Opt. Express. 2008, 16: 2153. ; COI number [1:CAS:528:DC%2BD1cXhvFansbk%3D]; Bibcode number [2008OExpr..16.2153A] 10.1364/OE.16.002153View ArticleGoogle Scholar
- Loo C, Hirsch L, Lee M, Chang E, West J, Halas N, Drezek R: Opt. Lett.. 2005, 30: 1012. ; COI number [1:CAS:528:DC%2BD2MXktlCjsLo%3D]; Bibcode number [2005OptL...30.1012L] 10.1364/OL.30.001012View ArticleGoogle Scholar
- Park J, Estrada A, Sharp K, Sang K, Schwartz JA, Smith DK, Coleman C, Payne JD, Korgel BA, Dunn AK, Tunnell JW: Opt. Express. 2008, 16: 1590. ; COI number [1:CAS:528:DC%2BD1cXhvFansbY%3D]; Bibcode number [2008OExpr..16.1590P] 10.1364/OE.16.001590View ArticleGoogle Scholar
- Zharov V, Galanzha E, Shashkov E, Khlebtsov N, Tuchin V: Opt. Lett.. 2006, 31: 3623. Bibcode number [2006OptL...31.3623Z] Bibcode number [2006OptL...31.3623Z] 10.1364/OL.31.003623View ArticleGoogle Scholar
- Mallidi S, Larson T, Aaron J, Sokolov K, Emelianov S: Opt. Express. 2007, 15: 6583. ; COI number [1:CAS:528:DC%2BD2sXntlGlsbY%3D]; Bibcode number [2007OExpr..15.6583M] 10.1364/OE.15.006583View ArticleGoogle Scholar
- Pissuwan D, Valenzuela SM, Cortie MB: Trends Biotechnol.. 2006, 24: 62. COI number [1:CAS:528:DC%2BD28XhtV2lsr8%3D] 10.1016/j.tibtech.2005.12.004View ArticleGoogle Scholar
- Khlebtsov BN, Zharov VP, Melnikov AG, Tuchin VV, Khlebtsov NG: Nanotechnology. 2006, 17: 5167. ; COI number [1:CAS:528:DC%2BD28Xht1OjtLbK]; Bibcode number [2006Nanot..17.5167K] 10.1088/0957-4484/17/20/022View ArticleGoogle Scholar
- Donnelly JJ, Wahren B, Liu MA: J. Immunol.. 2005, 175: 633. View ArticleGoogle Scholar
- Paciotti GF, Kingston DGI, Tamarkin L: Drug Dev. Res.. 2006, 67: 47. COI number [1:CAS:528:DC%2BD28XltF2msLc%3D] 10.1002/ddr.20066View ArticleGoogle Scholar
- Xu ZP, Zeng QH, Lu GQ, Yu AB: Chem. Eng. Sci.. 2006, 61: 1027. COI number [1:CAS:528:DC%2BD2MXht1aqur3P] 10.1016/j.ces.2005.06.019View ArticleGoogle Scholar
- Bergen JM, von Recum HA, Goodman TT, Massey AP, Pun SH: Macromol. Biosci.. 2006, 6: 506. COI number [1:CAS:528:DC%2BD28XnslChtbc%3D] 10.1002/mabi.200600075View ArticleGoogle Scholar
- Han G, Ghosh P, Rotello VM: Nanomedicine. 2007, 2: 113. COI number [1:CAS:528:DC%2BD2sXhvF2itrY%3D] 10.2217/174358188.8.131.52View ArticleGoogle Scholar
- Paciotti GF, Myer L, Weinreich D, Goia D, Pavel N, McLaughlin RE, Tamarkin L: Drug Deliv.. 2004, 11: 169. COI number [1:CAS:528:DC%2BD2cXks1aiurc%3D] 10.1080/10717540490433895View ArticleGoogle Scholar
- Chen Y-H, Tsai C-Y, Huang P-Y, Chang M-Y, Cheng P-C, Chou C-H, Chen D-H, Wang C-R, Shiau A-L, Wu C-L: Mol. Pharm.. 2007, 4: 713. COI number [1:CAS:528:DC%2BD2sXpt1Gitrs%3D] 10.1021/mp060132kView ArticleGoogle Scholar
- Li J, Wang X, Wang C, Chen B, Dai Y, Zhang R, Song M, Lv G, Fu D: ChemMedChem. 2007, 2: 374. COI number [1:CAS:528:DC%2BD2sXmtVWqu7w%3D] 10.1002/cmdc.200600264View ArticleGoogle Scholar
- Patra CR, Bhattacharya R, Wang E, Katarya A, Lau JS, Dutta S, Muders M, Wang S, Buhrow SA, Safgren SL, Yaszemski MJ, Reid JM, Ames MM, Mukherjee P, Mukhopadhyay D: Cancer Res.. 2008, 68: 1970. COI number [1:CAS:528:DC%2BD1cXjtFOhtrg%3D] 10.1158/0008-5472.CAN-07-6102View ArticleGoogle Scholar
- Joshi HM, Bhumkar DR, Joshi K, Pokharkar V, Sastry M: Langmuir. 2006, 22: 300. COI number [1:CAS:528:DC%2BD2MXht1Kkt7zF] 10.1021/la051982uView ArticleGoogle Scholar
- Nie Z, Liu KJ, Zhong C-J, Wang L-F, Yang Y, Tian Q, Liu Y: Free Radical Biol. Med.. 2007, 43: 1243. COI number [1:CAS:528:DC%2BD2sXhtVOis7nE] 10.1016/j.freeradbiomed.2007.06.011View ArticleGoogle Scholar
- Pissuwan D, Valenzuela SM, Miller CM, Cortie MB: Nano Lett.. 2007, 7: 3808. ; COI number [1:CAS:528:DC%2BD2sXhtlCks77O]; Bibcode number [2007NanoL...7.3808P] 10.1021/nl072377+View ArticleGoogle Scholar
- Huang W-C, Tsai P-J, Chen Y-C: Nanomedicine. 2007, 2: 777. COI number [1:CAS:528:DC%2BD1cXitlWgu7Y%3D] 10.2217/174358184.108.40.2067View ArticleGoogle Scholar
- Zharov VP, Mercer KE, Galitovskaya EN, Smeltzery MS: Biophys. J.. 2006, 90: 619. ; COI number [1:CAS:528:DC%2BD28XktlKrsg%3D%3D]; Bibcode number [2006BpJ....90..619Z] 10.1529/biophysj.105.061895View ArticleGoogle Scholar
- Gu H, Ho PL, Tong E, Wang L, Xu B: Nano Lett.. 2003, 3: 1261. ; COI number [1:CAS:528:DC%2BD3sXmsFOitr0%3D]; Bibcode number [2003NanoL...3.1261G] 10.1021/nl034396zView ArticleGoogle Scholar
- Rosemary MJ, MacLaren I, Pradeep T: Langmuir. 2006, 22: 10125. COI number [1:CAS:528:DC%2BD28XhtVyrsb7I] 10.1021/la061411hView ArticleGoogle Scholar
- Shrivastava S, Bera T, Roy A, Singh G, Ramachandrarao P, Dash D: Nanotechnology. 2007, 18: 225103. Bibcode number [2007Nanot..18v5103S] Bibcode number [2007Nanot..18v5103S] 10.1088/0957-4484/18/22/225103View ArticleGoogle Scholar
- Shahverdi AR, Fakhimi A, Shahverdi HR, Minaian S: Nanomedicine. 2007, 3: 168. View ArticleGoogle Scholar
- Zhang Y, Peng H, Huang W, Zhou Y, Yan D: J. Colloid Interface Sci.. 2008, 325: 371. COI number [1:CAS:528:DC%2BD1cXpvVKht7o%3D] 10.1016/j.jcis.2008.05.063View ArticleGoogle Scholar
- Grace AN, Pandian K: Colloids Surf. A: Physicochem. Eng. Asp.. 2007, 297: 63. COI number [1:CAS:528:DC%2BD2sXitFekuro%3D] 10.1016/j.colsurfa.2006.10.024View ArticleGoogle Scholar
- Grace AN, Pandian K: J. Bionanosci.. 2007, 1: 96. 10.1166/jbns.2007.018View ArticleGoogle Scholar
- Saha B, Bhattacharya J, Mukherjee A, Ghosh AK, Santra CR, Dasgupta AK, Karmakar P: Nanoscale Res. Lett.. 2007, 2: 614. ; COI number [1:CAS:528:DC%2BD1cXlslejsL8%3D]; Bibcode number [2007NRL.....2..614S] 10.1007/s11671-007-9104-2View ArticleGoogle Scholar
- Selvaraj V, Alagar M: Int. J. Pharm.. 2007, 337: 275. COI number [1:CAS:528:DC%2BD2sXlsFags7o%3D] 10.1016/j.ijpharm.2006.12.027View ArticleGoogle Scholar
- Khlebtsov NG, Dykman LA, Krasnov YM, Melnikov AG: Colloid J.. 2000, 62: 765. COI number [1:CAS:528:DC%2BD3MXhs1Srsw%3D%3D] 10.1023/A:1026643111821View ArticleGoogle Scholar
- Frens G: Nat. Phys. Sci.. 1973, 241: 20. ; ; View ArticleGoogle Scholar
- Khlebtsov NG: Anal. Chem.. 2008, 80: 6620. COI number [1:CAS:528:DC%2BD1cXoslKmtbk%3D] 10.1021/ac800834nView ArticleGoogle Scholar
- Shchyogolev SY, Khlebtsov NG, Schwartsburd BI: Proc. SPIE. 1993, 1981: 67. Bibcode number [1993SPIE.1981...67S] Bibcode number [1993SPIE.1981...67S] 10.1117/12.146490View ArticleGoogle Scholar